Andere Sprachen Elanco Animal Health Incorporated

Aktien

A2N6BH

US28414H1032

ELAN

Pharmazeutika

Markt geschlossen - Nyse Andere Börsenplätze 22:00:03 13.02.2026			% 5 Tage	Veränd. 1. Jan.
25,13 ^USD	+1,37 %		-0,28 %	+11,05 %

13.02.	Elanco Animal Health gibt den Rücktritt von David Hoover aus dem Vorstand bekannt	RE
13.02.	Elanco Animal Health Incorporated kündigt den Rücktritt von Vorstandsvorsitzendem R. David Hoover und Vorstandsmitglied Dr. Deborah Kochevar zur Hauptversammlung 2026 an	CI

Andere Sprachen

13.02.	Elanco Animal Health says David Hoover retires as a member of Elanco board
13.02.	Elanco Animal Health Incorporated Announces Retirement of Chairman R. David Hoover and Board Member Dr. Deborah Kochevar at 2026 Annual Meeting of Shareholders in May 2026
13.02.	Elanco Announces Updates to Board of Directors
13.02.	Elanco Animal Health Incorporated : Announces Updates to Board of Directors
22.01.	Elanco Animal Health Shares Rise After Piper Sandler Upgrade
22.01.	Escalate, De-Escalate, Repeat
22.01.	Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
22.01.	Analyst recommendations: Datadog, Albemarle, Halliburton, Netflix…
13.01.	Elanco CEO: Gaining Market Share Via 'Major' Innovations
06.01.	Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference
31.12.	Elanco Animal Health Gets USDA Approval for Canine-Dermatitis Treatment
31.12.	Elanco Animal Health Secures USDA Approval for Befrena Targeting Canine Allergic and Atopic Dermatitis
31.12.	Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis
31.12.	Elanco Animal Health Incorporated Receives USDA Approval for Befrena?? (tirnovetmab)
27.12.	3 géants français…et leur comparable américain méconnu
18.12.	Elanco's Credelio Quattro??-CA1 (Lotilaner, Moxidectin, Praziquantel, and Pyrantel Chewable Tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs
18.12.	Elanco Says Credelio Quattro-CA1 Got FDA Conditional Approval for Treatment of New World Screwworm in Dogs
18.12.	Elanco's Credelio Quattro(TM)-Ca1 receives first FDA conditional approval
18.12.	Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs
16.12.	L'Europe termine en repli après l'emploi américain
16.12.	Virbac : fait l'acquisition d'un traitement pour 114 millions d'euros
16.12.	Virbac acquiert un médicament pour l'hyperthyroïdie féline auprès de Norbrook pour £100 mlns
16.12.	Virbac acquiert les droits de distribution d'un médicament pour stabiliser l'hyperthyroïdie féline
16.12.	Virbac SA acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at ?100 million.
15.12.	Elanco Animal Health Incorporated : Announces Full USDA Approval of CPMA (Now Trutect™) the First-and-Only Treatment for Deadly Canine Parvovirus

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen MarketScreener Artikel MarketScreener Analysen Trading-Ideen

Filter

Schlagzeilen

Elanco-CEO: Blockbuster-Medikamente treiben das Geschäft voran

Am 09. September 2025 um 18:36 Uhr